Report
Economist Impact Study: Building Business Value in the Pharmaceutical Industry
Prepare for a resilient future
Dataminr commissioned Economist Impact to examine global businesses’ value creation
and resilience priorities via a survey of 600 executives across six industries. In this industry profile, we take a closer look at survey findings from respondents in the pharmaceutical industry.
Read the profile to learn how pharmaceutical companies are:
- Preparing for new challenges arising from geopolitical tensions
- Innovating through the use of technologies such as AI
- Finding a balance between physical and digital asset protection
71%
of pharma companies believe AI will have a positive impact on their ability to thrive in the next three years.
Get the report
Related resources
Report
Economist Impact Study: Building Business Value
Organizational, technological and operational resilience are the three key pillars for building overall resilience, says Dataminr-commissioned report.
Report
Mitigating Pharmaceutical Supply Chain Risk with Real-time Information
Learn how to maintain supply chain agility and resilience.
eBook
Best Practices: Pharma Risk Management
How lessons learned from the COVID-19 pandemic can strengthen pharmaceutical companies’ operational resilience and agility.